Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

4748 - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial

Date

09 Sep 2017

Session

Breast cancer, early stage

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Paolo Nuciforo

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

P. Nuciforo1, A. Prat2, A. Llombart3, R. Fasani1, L. Paré4, T. Pascual4, M. Oliveira5, N. Martínez Jañez6, B. Bermejo De Las Heras7, M. Vidal5, S. Pernas Simon8, R. López9, M. Muñoz10, I. Garau11, L. Manso12, J. Alarcon Company13, E. Martinez de Dueñas14, P. Villagrasa Gonzalez15, J. Cortes Castan16, E. Holgado16

Author affiliations

  • 1 Molecular Oncology Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Medical Oncology  , Hospital Clínic de Barcelona  , 8036 - Barcelona/ES
  • 3 Medical Oncology  , Hospital Universitario Arnau Vilanova de Lleida, 25198 - Lerida/ES
  • 4 Medical Oncology, IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer, 8036 - Barcelona/ES
  • 5 Medical Oncology Department, Vall d’Hebron University Hospital Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 6 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 7 Medical Oncology  , Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 8 Medical Oncology, Institut Català d'Oncologia (ICO)-Hospitalet, 08908 - Barcelona/ES
  • 9 Medical Oncology Department, Hospital Clínico de Santiago, Santiago de Compostela/ES
  • 10 Clinical Oncology, Hospital Clinic i Provincial de Barcelona, Barcelona/ES
  • 11 Medical Oncology  , Hospital de Son Llàtzer, Palma de Mallorca/ES
  • 12 Clinical Oncologist, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 13 Medical Oncology  , Hospital Universitario Son Espases, 7010 - Palma de Mallorca/ES
  • 14 Medical Oncology, Hospital Provincial de Castellón, Castellon/ES
  • 15 Scientific Department, SOLTI Breast Cancer Research Group, Barcelona/ES
  • 16 Oncology Service, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
More

Resources

Abstract 4748

Background

Increased number of TILs at baseline is associated with pathological complete response (pCR) and improved outcomes in HER2+ early breast cancer (BC) treated with anti-HER2-based chemotherapy. The associations in the neoadjuvant setting in the absence of chemotherapy and the effect of on-treatment TILs changes on pCR in the breast (pCRB) are unknown.

Methods

PAMELA is a prospective study in HER2+ BC designed to evaluate the ability of the PAM50 intrinsic subtypes (IS) to predict pCRB following neoadjuvant lapatinib and trastuzumab (with hormonal therapy if hormone receptor-positive[HR+]). Levels of TILs as continuous and categorical (TILs-low = 50%) variables and their changes were correlated with pCRB.

Results

TILs evaluation was available for 148 baseline (BS) and 134 Day-15 (D15) samples of 151 recruited patients. At BS, the median (interquartile range) levels of TILs were 10% (5-20). Median TILs distribution according to IS was: HER2-E (10%), Luminal (Lum) A (7.5%), LumB (5%), Basal-like (5%) (p = 0.02). Levels of TILs were higher in HR- (10%, 1-20) vs HR + (5%, 1-20) tumors, although not statistically significant (p = 0.07). pCRB rates were 58.3% (7/12) for TILs-high and 27.2% (37/136) for TILs-low (p = 0.03). At baseline, TILs were significantly associated with pCR in univariate analysis. At D15, median levels of TILs were 15% (5-30) with an increase across all the different IS (p 

Conclusions

The presence of TILs at D15 is an independent predictive marker of pCRB in HER2+ early BC treated with neoadjuvant anti-HER2 agents without chemotherapy.

Clinical trial identification

NCT01973660

Legal entity responsible for the study

SOLTI Breast Cancer Research Group

Funding

GlaxoSmithKline (now Novartis)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.